Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.75
SPPI's Cash to Debt is ranked higher than
60% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. SPPI: 1.75 )
SPPI' s 10-Year Cash to Debt Range
Min: 0.73   Max: 17918
Current: 1.75

0.73
17918
Equity to Asset 0.56
SPPI's Equity to Asset is ranked higher than
64% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SPPI: 0.56 )
SPPI' s 10-Year Equity to Asset Range
Min: 0.2   Max: 0.94
Current: 0.56

0.2
0.94
F-Score: 3
Z-Score: 1.05
M-Score: -3.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -24.89
SPPI's Operating margin (%) is ranked higher than
75% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. SPPI: -24.89 )
SPPI' s 10-Year Operating margin (%) Range
Min: -68658.54   Max: 30.17
Current: -24.89

-68658.54
30.17
Net-margin (%) -39.87
SPPI's Net-margin (%) is ranked higher than
72% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. SPPI: -39.87 )
SPPI' s 10-Year Net-margin (%) Range
Min: -67890.24   Max: 35.19
Current: -39.87

-67890.24
35.19
ROE (%) -22.06
SPPI's ROE (%) is ranked higher than
70% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. SPPI: -22.06 )
SPPI' s 10-Year ROE (%) Range
Min: -2624.11   Max: 32.63
Current: -22.06

-2624.11
32.63
ROA (%) -12.45
SPPI's ROA (%) is ranked higher than
74% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. SPPI: -12.45 )
SPPI' s 10-Year ROA (%) Range
Min: -510.69   Max: 18.66
Current: -12.45

-510.69
18.66
ROC (Joel Greenblatt) (%) -2526.71
SPPI's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. SPPI: -2526.71 )
SPPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5194.83   Max: 3170.09
Current: -2526.71

-5194.83
3170.09
Revenue Growth (%) 19.70
SPPI's Revenue Growth (%) is ranked higher than
90% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. SPPI: 19.70 )
SPPI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 211.9
Current: 19.7

0
211.9
EBITDA Growth (%) -34.00
SPPI's EBITDA Growth (%) is ranked higher than
58% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. SPPI: -34.00 )
SPPI' s 10-Year EBITDA Growth (%) Range
Min: -70.9   Max: 108.9
Current: -34

-70.9
108.9
EPS Growth (%) 2.40
SPPI's EPS Growth (%) is ranked higher than
83% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. SPPI: 2.40 )
SPPI' s 10-Year EPS Growth (%) Range
Min: -71.4   Max: 131.1
Current: 2.4

-71.4
131.1
» SPPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SPPI Guru Trades in Q1 2013

Steven Cohen 2,500 sh (New)
Paul Tudor Jones 85,100 sh (+286.82%)
» More
Q2 2013

SPPI Guru Trades in Q2 2013

Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q3 2013

SPPI Guru Trades in Q3 2013

Jim Simons 12,017 sh (New)
» More
Q4 2013

SPPI Guru Trades in Q4 2013

Paul Tudor Jones 13,000 sh (New)
Jim Simons 69,517 sh (+478.49%)
» More
» Details

Insider Trades

Latest Guru Trades with SPPI

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2012-12-31 Sold Out 0.13%$10.64 - $12.31 $ 7.18-37%0
Joel Greenblatt 2012-12-31 Sold Out 0.02%$10.64 - $12.31 $ 7.18-37%0
Joel Greenblatt 2012-12-31 Sold Out 0.02%$10.64 - $12.31 $ 7.18-37%0
John Burbank 2012-09-30 New Buy0.13%$11.6 - $17.05 $ 7.18-48%250000
Joel Greenblatt 2012-09-30 New Buy0.02%$11.6 - $17.05 $ 7.18-48%19901
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.64
SPPI's P/B is ranked higher than
92% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. SPPI: 1.64 )
SPPI' s 10-Year P/B Range
Min: 0.54   Max: 5.23
Current: 1.64

0.54
5.23
P/S 2.80
SPPI's P/S is ranked higher than
86% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. SPPI: 2.80 )
SPPI' s 10-Year P/S Range
Min: 1.07   Max: 367
Current: 2.8

1.07
367
EV-to-EBIT -9.86
SPPI's EV-to-EBIT is ranked higher than
53% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. SPPI: -9.86 )
SPPI' s 10-Year EV-to-EBIT Range
Min: 5.6   Max: 63.5
Current: -9.86

5.6
63.5

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.65
SPPI's Price/Tangible Book is ranked lower than
73% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. SPPI: 14.65 )
SPPI' s 10-Year Price/Tangible Book Range
Min: 1.3   Max: 37.25
Current: 14.65

1.3
37.25
Price/DCF (Projected) 1.64
SPPI's Price/DCF (Projected) is ranked higher than
87% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. SPPI: 1.64 )
SPPI' s 10-Year Price/DCF (Projected) Range
Min: 2.02   Max: 11.52
Current: 1.64

2.02
11.52
Price/Median PS Value 0.57
SPPI's Price/Median PS Value is ranked higher than
91% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. SPPI: 0.57 )
SPPI' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 1325
Current: 0.57

0.24
1325
Earnings Yield (Greenblatt) 4.40
SPPI's Earnings Yield (Greenblatt) is ranked higher than
62% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. SPPI: 4.40 )
SPPI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 17.7
Current: 4.4

1.6
17.7
Forward Rate of Return (Yacktman) 1.90
SPPI's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. SPPI: 1.90 )
SPPI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.6   Max: 0.5
Current: 1.9

-9.6
0.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NTR.Germany
Spectrum Pharmaceuticals Inc is a Delaware corporation that was originally incorporated in Colorado as Americus Funding Corporation in December 1987, became NeoTherapeutics, Inc. in August 1996, was reincorporated in Delaware in June 1997, and was renamed Spectrum Pharmaceuticals, Inc. in December 2002. The Company is a biotechnology company integrated with commercial and drug development operations primarily in hematology and oncology. It markets three oncology drugs, FUSILEV , FOLOTYN and ZEVALIN and also market ZEVALIN outside of the U.S. The Company has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of novel drug candidates. The Company has assembled an integrated in-house scientific team, including formulation development, clinical development, medical affairs, regulatory affairs, biostatistics and data management, and has established a commercial infrastructure for the marketing of its drug products. The Company product portfolio is consist of both commercial stage and development stage products. The Company's products are manufactured on a contract basis. It has built and develop, a sales and marketing infrastructure as part of its commercialization efforts for FUSILEV, ZEVALIN and FOLOTYN. The Company have limited number of customers which include Oncology Supply, McKesson Specialty, ICS and Cardinal Health. The Company competes with Abraxis Bioscience, Inc., Astra Zeneca LP, Bayer AG, Endo Pharmaceuticals, Eli Lilly and Co., Novartis Pharmaceuticals, Corporation, Genentech, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, Biogen-IDEC Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., Cephalon, Inc., Sanofi-Aventis, Inc., Pfizer, Inc., Genta Incorporated, Merck, Celgene Corporation, BiPar Sciences, Inc., Genzyme Corporation, Shire Pharmaceuticals, Abbott Laboratories, Poniard Pharmaceuticals, Inc., Roche Pharmaceuticals and Johnson & Johnson. The development, production and marketing of the company's proprietary and generic drug and biologic products are subject to regulation for safety, efficacy and quality by numerous governmental authorities in the U.S. and other countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide